Federal Register Notice: FDA is making available a draft guidance for industry, Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products. It encourages manufacturers of medically necessary drug products (MNPs) and components to develop contingency production plans in the event of an emergency that results in high absenteeism at one or more production. To download this guidance, click here. To view this notice, click here.